GH Form 4: Director Myrtle Potter Disposes of 26 Shares

Rhea-AI Filing Summary

Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported an open-market sale of 26 shares of the company's common stock on 08/19/2025 at a price of $59.02 per share. After the reported transaction, Potter beneficially owned 18,239 shares. The Form 4 indicates the filing was executed by an attorney-in-fact and filed on 08/20/2025. The form is marked as a sale pursuant to a written plan under Rule 10b5-1.

Insights

Securities Analyst

TL;DR: Small, routine insider sale by a director; appears non-material to company valuation.

The Form 4 documents a minor disposition of 26 shares by Director Myrtle S. Potter at $59.02 each, leaving total beneficial ownership of 18,239 shares. The filing is marked as made pursuant to a written plan consistent with Rule 10b5-1, which typically signals pre-planned, non-discretionary trades. Given the small size of the sale relative to typical outstanding shares for a public company, this transaction is unlikely to be material to Guardant Health's market capitalization or signal a change in company fundamentals.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16; use of a 10b5-1 plan reduces questions about timing.

The report identifies Myrtle S. Potter as a director and indicates the transaction was executed under a written 10b5-1 plan, which provides an affirmative defense against insider trading claims when conditions are met. The Form 4 was signed by an attorney-in-fact, which is permitted for Section 16 filings. There are no indications of amendments or additional disclosures in this filing.

08/20/2025 - 07:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POTTER MYRTLE S

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		S		26	D	$59.02	18,239	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Myrtle S. Potter	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Guardant Health (GH) report on this Form 4?

Director Myrtle S. Potter reported a sale of 26 shares of Guardant Health common stock on 08/19/2025 at $59.02 per share.

How many Guardant Health shares does Myrtle S. Potter beneficially own after the reported sale?

Following the reported transaction, Myrtle S. Potter beneficially owned 18,239 shares.

Was the transaction reported as part of a 10b5-1 plan for GH insider trades?

Yes, the Form 4 is checked to indicate the transaction was made pursuant to a written plan intended to satisfy the Rule 10b5-1(c) affirmative defense.

When was the Form 4 filed and who signed it?

The filing is dated 08/20/2025 and was signed by /s/ John G. Saia, as attorney-in-fact for Myrtle S. Potter.